Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @johnkang64
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @johnkang64
-
John Kang proslijedio/la je Tweet
The anti-cancer efficacy and specificity of magrolimab (formerly known as 5F9), our antibody versus
#CD47, involves tipping the balance between the “eat me” and “don’t eat me” signals received by macrophages when they encounter a potential target cell.pic.twitter.com/v8ylOHPEhSHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A thoughtful piece by
@timlu from@SentiBio on how#genecircuits will empower next-generation cell & gene therapieshttps://www.genengnews.com/insights/gene-circuits-empower-next-generation-cell-and-gene-therapies/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing -https://endpts.com/how-much-does-it-cost-to-bootstrap-a-gene-therapy-startup-not-too-much-if-youre-jim-wilson-per-passage-bios-125m-ipo-filing/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Crazy fact: Cutting-edge disease cures powered by gene therapy and CRISPR still rely on a toxic drug from the 1950s. I wrote about efforts to fix that problem with new, safer bone marrow conditioning regimens. Featuring
$MGTA$FTSVhttps://www.statnews.com/2019/12/18/cutting-edge-therapies-promise-one-time-cures-risk-safety/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Perks of having an HDMZ SF office? Avoiding all the
#JPM20 traffic. P.S. the outfit coordination in the second was unintentional but perfect
#JPMorgan2020#JPMHC20#JPM2020pic.twitter.com/GIamH5xaQp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
From
#BaseEditing to#GeneCircuits to#chromatin,#GeneTherapy is rapidly evolving Read more in Special Report: Finding the pathfinders, w/@HorizonGenomics@SentiBio@OmegaTX &@UVicResearch http://ddn-news.com/index.php?newsarticle=13891 …#genomics#epigenetics@timlu@MPK_LifeSci@Tuck_RKstarpic.twitter.com/sL0HXKSFKH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
I'm happy to announce that I'll be presenting our latest updates on
#genecircuit therapies at@SentiBio at the JP Morgan conference, Wednesday, January 15, 2020 @ 11 AM in the Elizabethan D room at Westin St. Francis!#JPM20#JPMG2020!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Nature has often evolved redundant systems to achieve any outcome This can be why cancer drugs struggle to remain effective But it can also be used by researchers to attempt an end-run around a clinical challenge like, in this case, sickle cell anemiahttps://twitter.com/DDNewsOnline/status/1207420274804588544 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Added a new name to my list of local companies developing beta thalassemia drugs —
@SyrosPharma has partnered up with Global Blood Therapeutics to develop a drug in a deal with $20M upfront and $355M in research funds/milestones$SYRSpic.twitter.com/6cZDafRJBT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
.
@SyrosPharma identifies repressor of fetal#hemoglobin gene, possible target for#SickleCell disease Tell#ASH19, knocking down NFIX increases γ-globin mRNA, detectable fetal hemoglobin in 100% of cells https://www.syros.com/platform#hematology@ASH_hematology@SternIR@HDMZHealthpic.twitter.com/3fTZPkcnE4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Closing question from
@sxbegle: If you are as successful as you hope to be, what do you want the first paragraph of your Wikipedia entry to say in 20 years? Wilson: "That I was the Johnny Appleseed of gene therapy."pic.twitter.com/y9yupUlKoC
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Big news from
@CRISPRTX and@VertexPharma this morning about their CTX001 CRISPR/Cas9 therapy for sickle cell disease + beta-thalassemia. I covered the science of this therapy for@cenmag back in 2018. Goal is to break BCL11A and boost fetal hemoglobin: https://cen.acs.org/articles/96/i2/CRISPR-coming-clinic-year.html …pic.twitter.com/fHqC6dUH4u
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
John Kang proslijedio/la je Tweet
Check out this article about our SENTI-101
#SITC2019 poster presentation.#genecircuits#genetherapy#celltherapy#immunotherapyhttps://twitter.com/BioCentury/status/1191830139056857089 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
V. interesting deal this morning between
$BLUE and$FTSV to develop antibody-based conditioning for stem-cell based gene therapies like Zynteglo. Current conditioning uses chemo or radiation to prepare bone marrow for engraftment, which isn't ideal.http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-forty-seven-announce-research-collaboration …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
AML, safety data for magrolimab help Forty Seven shares regain lost ground
#ASH19$FTSVhttps://buff.ly/2pEqD4DHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Excited to announce the publication of the abstract for our poster presentation at
#SITC2019 on 11/9 describing our preclinical efficacy data for SENTI-101, a novel allogeneic cell product. https://www.sentibio.com/press-release/press-release-detail/view_express_entity/71 …#genecircuits#genetherapy#celltherapy#immunotherapy#biotechHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Check out our CEO and co-founder
@timlu 's TEDMED Talk about biological engineering, released today!#genecircuits#genetherapy#syntheticbiologyhttps://www.tedmed.com/talks/show?id=730076 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Our CEO and co-founder,
@timlu, presented today at ARM's Cell & Gene Meeting on the Mesa to share our company's story and the rapid progress our team has made in the field of gene circuit therapies. Connect with@timlu and Curt Herberts at this week's conference.#genecircuitspic.twitter.com/bx2PIMuu1a
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
John Kang proslijedio/la je Tweet
Happy to RT but already shopped
https://twitter.com/christineliuart/status/1187027362564792321 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
